BR0210631A - Composição farmacêutica de liberação prolongada - Google Patents

Composição farmacêutica de liberação prolongada

Info

Publication number
BR0210631A
BR0210631A BR0210631-0A BR0210631A BR0210631A BR 0210631 A BR0210631 A BR 0210631A BR 0210631 A BR0210631 A BR 0210631A BR 0210631 A BR0210631 A BR 0210631A
Authority
BR
Brazil
Prior art keywords
extended release
pharmaceutical composition
composition
release pharmaceutical
mini
Prior art date
Application number
BR0210631-0A
Other languages
English (en)
Inventor
Serge R Martinod
Malcolm Brandon
Original Assignee
Smart Drug Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smart Drug Systems Inc filed Critical Smart Drug Systems Inc
Publication of BR0210631A publication Critical patent/BR0210631A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA DE LIBERAçãO PROLONGADA". Aparelho de liberação prolongada incluindo uma pluralidade de mini-implantes ou pelotas para liberação prolongada, cada mini-implante incluindo um material de suporte de liberação prolongada, e uma composição farmaceuticamente ativa conduzida no material suporte de liberação prolongada ou sobre ele, incluindo a composição farmaceuticamente ativa pelo menos um componente farmaceuticamente ativo, e um veículo para o mesmo, cada implante sendo de tamanho e/ou carga comercial insuficiente, individual para dar um predeterminado nível sang³íneo limítrofe desejado do ativo farmacêutico para tratamento de uma indicação selecionada.
BR0210631-0A 2001-06-29 2002-07-01 Composição farmacêutica de liberação prolongada BR0210631A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR6025A AUPR602501A0 (en) 2001-06-29 2001-06-29 Sustained release pharmaceutical composition
PCT/AU2002/000865 WO2003002102A1 (en) 2001-06-29 2002-07-01 Sustained release pharmaceutical composition

Publications (1)

Publication Number Publication Date
BR0210631A true BR0210631A (pt) 2004-07-27

Family

ID=3829991

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210631-0A BR0210631A (pt) 2001-06-29 2002-07-01 Composição farmacêutica de liberação prolongada

Country Status (10)

Country Link
US (1) US20040241204A1 (pt)
EP (1) EP1411904A4 (pt)
JP (1) JP4800570B2 (pt)
CN (1) CN1731988A (pt)
AU (2) AUPR602501A0 (pt)
BR (1) BR0210631A (pt)
CA (1) CA2452030A1 (pt)
CO (1) CO5540373A2 (pt)
NZ (1) NZ529859A (pt)
WO (1) WO2003002102A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129728A1 (en) * 2001-09-11 2005-06-16 Martinod Serge R. Sustained release pharmaceutical composition
JP2005522418A (ja) * 2002-01-24 2005-07-28 スマート ドラッグ システムズ インコーポレイティド 徐放性医薬組成物
EP1755636A1 (en) * 2004-05-31 2007-02-28 Smart Drug Systems Inc. Sustained release composition
AU2005253646B2 (en) * 2004-06-16 2011-09-15 Virbac Corporation Sustained release vaccine composition
US9750797B2 (en) * 2004-06-16 2017-09-05 Virbac Corporation Sustained release vaccine composition
EP1781264B1 (en) 2004-08-04 2013-07-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
EP1859788A1 (en) * 2006-05-24 2007-11-28 Abbott GmbH & Co. KG Production of enveloped pharmaceutical dosage forms
NZ552290A (en) * 2006-12-21 2009-05-31 Bomac Research Ltd Tablet fomulation
BRPI0705822A2 (pt) * 2007-10-25 2009-06-23 Schering Plough Saude Animal Ltda formulação injetável com ação prolongada e uso de um agente semi-sintético derivado do grupo das avermectinas, em combinação com um polìmero biodegradável
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
WO2010054296A2 (en) * 2008-11-07 2010-05-14 Combinent Biomedical Systems, Inc. Devices and methods for treating and/or preventing diseases
AR075846A1 (es) 2009-03-17 2011-04-27 Organon Nv Sistema de administracion de farmaco de lactona macrociclica.uso. metodo de tratamiento
KR20130083393A (ko) * 2010-06-01 2013-07-22 백스터 인터내셔널 인코포레이티드 건조 및 안정한 지혈 조성물의 제조 방법
JP5981430B2 (ja) * 2010-07-30 2016-08-31 セヴァ サンテ アニマレＣｅｖａ Ｓａｎｔｅ Ａｎｉｍａｌｅ ハートワーム感染を治療するための組成物
JP5696279B2 (ja) * 2010-12-01 2015-04-08 学校法人自治医科大学 長期徐放型薬剤硬膜外腔留置システム
CA3082432C (en) 2011-12-02 2023-01-03 Boehringer Ingelheim Animal Health USA Inc. Long-acting injectable moxidectin formulations and novel moxidectin crystal forms
US20130190839A1 (en) * 2012-01-20 2013-07-25 Jane Rapsey Drug delivery using a sacrificial host
WO2014160026A2 (en) * 2013-03-14 2014-10-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof
AU2013209343B1 (en) * 2013-05-14 2014-04-24 Activesignal Holding Limited Device for the Treatment of Bone Conditions
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
ITUB20153652A1 (it) 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
CN110559431B (zh) * 2019-10-11 2023-02-28 南京农业大学 一种巨型艾美耳球虫纳米亚单位疫苗及其制备方法和应用
FI4037666T3 (fi) 2020-12-08 2024-06-24 Ruminant Biotech Corp Ltd Parannuksia laitteisiin ja menetelmiin aineiden toimittamiseksi eläimille

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US4053580A (en) * 1975-01-01 1977-10-11 G. D. Searle & Co. Microsealed pharmaceutical delivery device
US4331652A (en) * 1979-09-12 1982-05-25 Eli Lilly And Company Controlled release parasitic formulations and method
US4723958A (en) * 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
DK0463061T3 (da) * 1989-03-17 1993-07-12 Pitman Moore Inc Controlled-release tilførselsindretning til afgivelse af makromolekylære proteiner
AU632827B2 (en) * 1989-06-21 1993-01-14 Brown University Research Foundation Neurological therapy system
FR2653338B1 (fr) * 1989-10-23 1994-06-10 Dow Corning Sa Formulation pour des pansements a liberation prolongee de medicament et son utilisation.
JPH11508224A (ja) * 1990-08-09 1999-07-21 エンドコン・インコーポレーテッド 多重ドラッグデリバリーシステム
NZ239370A (en) * 1990-08-22 1994-04-27 Merck & Co Inc Bioerodible implantable controlled release dosage form comprising a poly(ortho ester) or a polyacetal with an active agent incorporated into the chain backbone
US5211951A (en) * 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
JPH06321803A (ja) * 1993-05-17 1994-11-22 Kirin Brewery Co Ltd 水溶性ペプチドホルモンの徐放性製剤
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
FR2745180B1 (fr) * 1996-02-23 1998-05-07 Dow Corning Sa Procede de fabrication de dispositifs a liberation controlee
CA2304283A1 (en) * 1997-09-23 1999-04-01 Pfizer Limited Parasiticidal formulations
AUPP279698A0 (en) * 1998-04-03 1998-04-30 Sunscape Developments Limited Sustained release formulation
WO2000003660A1 (en) * 1998-07-17 2000-01-27 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
GB9816132D0 (en) * 1998-07-24 1998-09-23 Norbrook Lab Ltd Non-aqueous anthelmintic composition
WO2000013666A1 (en) * 1998-09-05 2000-03-16 Seung Jin Lee Biodegradable particulate polymeric preparation and process for producing thereof
US6645192B2 (en) * 1998-09-30 2003-11-11 Ivy Animal Health, Inc. Pellet implant system for immediate and delayed release of antiparasitic drug
JP2002525311A (ja) * 1998-10-01 2002-08-13 エラン ファーマ インターナショナル，リミティド 徐放性ナノ粒子組成物
CN1378445B (zh) * 1999-08-06 2013-02-06 得克萨斯系统大学评议会 药物释放生物可降解纤维植入物
TW524696B (en) * 1999-11-10 2003-03-21 Sumitomo Pharma Sustained-release drug formulations
AU1556000A (en) * 1999-11-22 2001-06-04 Akzo Nobel N.V. Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
US20020131988A1 (en) * 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix

Also Published As

Publication number Publication date
US20040241204A1 (en) 2004-12-02
WO2003002102A1 (en) 2003-01-09
CO5540373A2 (es) 2005-07-29
AUPR602501A0 (en) 2001-07-26
AU2002344685B2 (en) 2008-05-15
EP1411904A1 (en) 2004-04-28
CN1731988A (zh) 2006-02-08
JP2004530721A (ja) 2004-10-07
JP4800570B2 (ja) 2011-10-26
CA2452030A1 (en) 2003-01-09
EP1411904A4 (en) 2006-06-07
NZ529859A (en) 2005-11-25

Similar Documents

Publication Publication Date Title
BR0210631A (pt) Composição farmacêutica de liberação prolongada
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
BR0115531A (pt) Tratamento de mucosites
BR0007487A (pt) Difenil-uréias substituìdas com w-carbóxi-arilas como inibidores de raf cinase
HUP0002935A2 (hu) Gyomorban visszatartott, szabályozott hatóanyag kibocsátású mikrogömböcskék javított gyógyszeradagolás elősegítésére
ES2181691T3 (es) Sistema de distribucion de droga eritropoyetina.
BR0212052A (pt) Preparação de composição farmacêutica de liberação prolongada
BR0107942A (pt) Polìmeros de proteìna de liberação lenta
TW200505402A (en) Ophthalmic drug delivery device
ATE266422T1 (de) Pharmazeutische hydrogelformulierungen, vorrichtungen zur arzneistoffabgabe und verfahren
BRPI0407747A (pt) agente terapêutico para lesão à medula espinhal compreendendo antagonista de interleucinas-6
ATE74752T1 (de) Biologisch erodierbares system mit gesteuerter freisetzung des arzneiwirkstoffes.
DE60023520D1 (de) Flüssiges hochvisköses system mit gesteuerter freisetzung und medizinische oder chirurgische vorrichtung
NO953278L (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
ATE245450T1 (de) Haftende mikrokügelchen umfassende zusammensetzung zur arzneimittelgabe
BR0210630A (pt) Sistema fornecedor de liberação prolongada
SE9704401D0 (sv) Matrix pellets for greasy, oily or sticky drug substances
DE69716469D1 (de) Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol
DZ3473A1 (fr) Formulation pharmaceutique a liberation prolongee independante de la force ionique.
NZ509894A (en) A "T" or "Y" shaped intravaginal device suitable for delivery of pharmaceuticals such as progesterone
PT770384E (pt) Composicoes farmaceuticas solidas anidras para utilizacao vaginal
CY1108482T1 (el) Συστημα υποδοριας διανομης, μεθοδος παρασκευης του και χρηση του για την αγωγη διαταραχων xολινεργικης ανεπαρκειας
HUP0100303A2 (hu) Porózus hidroxiapatit részecskék mint gyógyszerhatóanyag hordozók
BR0214159A (pt) Sistema farmacêutico radiopaco de liberação prolongada
DK0904063T3 (da) Fremgangsmåde til fremstilling af mikropartikler

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: VIRBAC CORPORATION (US)

Free format text: TRANSFERIDO DE: SMART DRUG SYSTEMS INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2313 DE 05-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 9/00 (2006.01), A61K 31/365 (2006.01), A61K 3